CELLPOINT

cellpoint-logo

CellPoint is dedicated to developing CAR-T therapies at the point of care, making these therapies more affordable and accessible to patients. CellPoint has developed a 6-day manufacturing process, powered by its proprietary xCellit real-time monitoring software system, that allows for 1 week of vein-to-vein time compared to over one month with current industrial manufacturing platforms.

#People #Website #More

CELLPOINT

Social Links:

Industry:
Biotechnology Health Care

Founded:
2018-01-01

Address:
Oegstgeest, Zuid-Holland, The Netherlands

Country:
The Netherlands

Website Url:
http://www.cellpoint.bio

Total Employee:
1+

Status:
Active

Contact:
+31 712077810

Email Addresses:
[email protected]

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Apache Wordpress Plugins



Current Advisors List

eytan-abraham_image

Eytan Abraham Board Observer @ CellPoint
Board_observer
2021-01-01

Official Site Inspections

http://www.cellpoint.bio Semrush global rank: 4.26 M Semrush visits lastest month: 2.73 K

  • Host name: server-99-86-229-104.iad79.r.cloudfront.net
  • IP address: 99.86.229.104
  • Location: Seattle United States
  • Latitude: 47.54
  • Longitude: -122.3032
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98108

Loading ...

More informations about "CellPoint"

CellPoint - Galapagos

CellPoint was a biotechnology company founded in 2018 in the Netherlands. They developed a decentralized T-cell manufacturing platform. In 2022 CellPoint was acquired by Galapagos. Since then, they have been united around a โ€ฆSee details»

CellPoint - Crunchbase Company Profile & Funding

CellPoint is dedicated to developing CAR-T therapies at the point of care, making these therapies more affordable and accessible to patients. CellPoint has developed a 6-day manufacturing โ€ฆSee details»

CellPoint - LinkedIn

CellPoint | 4,526 followers on LinkedIn. CellPoint enables clinicians to treat hematological malignancies by retargeting patient immune cells at the point-of-care. In 2022, CellPoint was โ€ฆSee details»

AboundBio & CellPoint acquisition - Galapagos

CellPointโ€™s CAR-T cell-therapy is of investigational nature and is not approved by the FDA or any other regulatory authority forany use. Its efficacy and safety have not been established. โ€ฆSee details»

Galapagos to acquire CellPoint and AboundBio to accelerate

Jun 21, 2022 More information at www.cellpoint.bio. About AboundBio AboundBio is an innovative privately held biotechnology company whose mission is to generate novel antibody โ€ฆSee details»

Galapagos to acquire CellPoint and AboundBio to advance cell โ€ฆ

Jun 22, 2022 Under the terms of the agreements, Galapagos is to acquire all outstanding shares of CellPoint and AboundBio in an all-cash transaction against payment of an upfront amount of โ€ฆSee details»

Galapagos NV (GLPG) Acquires CellPoint and AboundBio

Jun 21, 2022 More information at www.cellpoint.bio. About AboundBio AboundBio is an innovative privately held biotechnology company whose mission is to generate novel antibody โ€ฆSee details»

Galapagos to acquire CellPoint and AboundBio to accelerate โ€ฆ

Jun 21, 2022 About CellPoint CellPoint is dedicated to developing CAR-T therapies at the point-of-care, making these therapies more affordable and accessible to patients. CellPoint has โ€ฆSee details»

Galapagos to buy CellPoint, AboundBio to boost โ€ฆ

Jun 22, 2022 Galapagos has signed agreements to acquire all outstanding shares of CellPoint and AboundBio to boost access to next-generation cell therapies, in an all-cash deal totalling $251m. Under the definitive agreements โ€ฆSee details»

CellPoint - Company Profile - Tracxn

Nov 16, 2024 CellPoint ranks 199th among 311 active competitors. 122 of its competitors are funded while 76 have exited. Overall, CellPoint and its competitors have raised over $14B in โ€ฆSee details»

Galapagos to acquire CellPoint and AboundBio to โ€ฆ

Jun 22, 2022 Galapagos NV, CellPoint and AboundBio announced that both companies have entered into definitive agreements with Galapagos, propelling Galapagos into next-generation cell therapy while significantly broadening its โ€ฆSee details»

Galapagos to acquire CellPoint and AboundBio to accelerate โ€ฆ

Jun 23, 2022 CellPoint has developed, in a strategic collaboration with Lonza, a novel point-of-care supply model, which offers the potential for efficient, 7-day delivery of CAR-T therapies โ€ฆSee details»

Galapagos, with latest deals, charts an unexpected journey to cell ...

Jun 22, 2022 Galapagos intends to buy Cellpoint through an upfront payment of 125 million euros, or roughly $131 million, with another 100 million euros contingent upon the โ€ฆSee details»

Galapagos to acquire CellPoint and AboundBio to accelerate โ€ฆ

Jun 21, 2022 All cash acquisition of CellPoint for an upfront amount of โ‚ฌ125 million, with milestone payments up to โ‚ฌ100 million and AboundBio for $14 million Webcast presentation โ€ฆSee details»

Galapagos shifts gears with Cellpoint, Aboundbio acquisitions

Galapagos NV is making a decisive shift away from its small-molecule roots, sealing the simultaneous acquisition of CAR T-cell therapy specialist Cellpoint BV and fully-human โ€ฆSee details»

Galapagos to acquire CellPoint and AboundBio to accelerate โ€ฆ

Jun 21, 2022 All cash acquisition of CellPoint for an upfront amount of โ‚ฌ125 million, with milestone payments up to โ‚ฌ100 million and AboundBio for $14 million. Webcast presentation โ€ฆSee details»

CellPoint Overview | SignalHire Company Profile

CellPoint enables clinicians to treat hematological malignancies by retargeting patient immune cells at the point-of-care.Get in touch or visit our website: https://cellpoint.bio Organization โ€ฆSee details»

CellPoint and Hypertrust Patient Data Care co-develop xCellit โ€ฆ

Nov 30, 2021 About CellPoint. CellPoint is a Dutch (EU) company founded to provide affordable and readily available CAR-T therapies for all patients in need. The CellPoint CAR-T treatment โ€ฆSee details»

Office manager - cellpoint.bio

CellPoint BV, BioPartner Center, De Limes 7 , 23 42 D H Oegstgeest , The Netherlands www.cellpoint.bio Office manager Oegstgeest , The Netherlands About CellPoint Engineering โ€ฆSee details»

CellPoint: bringing autologous CAR Ts to point of care

Jun 23, 2021 Emerging Company Profile: CellPoint aims to broaden access to CAR Ts with point-of-care manufacturing platform By Virginia Li, Associate Editor June 23, 2021 12:32 PM โ€ฆSee details»